Advertisement

Cardiovascular disease in patients with chronic kidney disease

Kardiovaskuläre Erkrankungen bei Patienten mit chronischer Niereninsuffizienz

  • 53 Accesses

Abstract

Patients with chronic kidney disease (CKD) are at increased risk for kidney failure, cardiovascular disease (CVD), and death. In fact, the likelihood of dying from CVD is markedly higher than that for reaching end-stage renal disease. Evidence-based management of comorbidities such as CVD remains challenging in patients with advanced CKD, as they were usually excluded from randomized controlled trials. This review focuses on the epidemiology, risk factors, and clinical manifestations of CVD in patients with advanced CKD. Specific topics of interest include diagnostic and therapeutic challenges of heart failure, coronary artery disease, and atrial fibrillation.

Zusammenfassung

Patienten mit chronischer Nierenerkrankung („chronic kidney disease“, CKD) weisen ein erhöhtes Risiko für Nierenversagen, Herz-Kreislauf-Erkrankungen („cardiovascular disease“, CVD) und Tod auf. Die Wahrscheinlichkeit, durch eine CVD zu sterben, ist höher als die Wahrscheinlichkeit, aufgrund terminaler Niereninsuffizienz dialysepflichtig zu werden. Evidenzbasierte Therapien von Komorbiditäten wie CVD bleiben bei Patienten mit fortgeschrittener CKD eine Herausforderung, da diese Patienten üblicherweise aus randomisierten kontrollierten Studien ausgeschlossen werden. Diese Übersichtsarbeit fokussiert auf die Epidemiologie, Risikofaktoren und klinischen Manifestationen von CVD bei Patienten mit fortgeschrittener CKD. Speziell hervorgehobene Themen sind die diagnostischen und therapeutischen Herausforderungen bei Herzinsuffizienz, koronarer Herzkrankheit und Vorhofflimmern.

This is a preview of subscription content, log in to check access.

Access options

Buy single article

Instant unlimited access to the full article PDF.

US$ 39.95

Price includes VAT for USA

Fig. 1
Fig. 2

References

  1. 1.

    Hill NR, Fatoba ST, Oke JL, Hirst JA, O’Callaghan CA, Lasserson DS et al (2016) Global prevalence of chronic kidney disease—a systematic review and meta-analysis. PLoS ONE 11(7):e158765

  2. 2.

    Tonelli M, Wiebe N, Manns BJ, Klarenbach SW, James MT, Ravani P et al (2018) Comparison of the complexity of patients seen by different medical Subspecialists in a universal health care system. JAMA Netw Open 1(7):e184852

  3. 3.

    Organization WH (2018) Mortality and global health estimates: causes of death; projections for 2015–2030; projection of death rates. WHO, Geneva

  4. 4.

    Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C‑Y (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351(13):1296–1305

  5. 5.

    Thompson S, James M, Wiebe N, Hemmelgarn B, Manns B, Klarenbach S et al (2015) Cause of death in patients with reduced kidney function. J Am Soc Nephrol 26(10):2504–2511

  6. 6.

    Wanner C, Amann K, Shoji T (2016) The heart and vascular system in dialysis. Lancet 388(10041):276–284

  7. 7.

    Stenvinkel P, Carrero JJ, Axelsson J, Lindholm B, Heimburger O, Massy Z (2008) Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? Clin J Am Soc Nephrol 3(2):505–521

  8. 8.

    Kooman JP, Kotanko P, Schols AM, Shiels PG, Stenvinkel P (2014) Chronic kidney disease and premature ageing. Nat Rev Nephrol 10(12):732–742

  9. 9.

    Anker SD, Gillespie IA, Eckardt KU, Kronenberg F, Richards S, Drueke TB et al (2016) Development and validation of cardiovascular risk scores for haemodialysis patients. Int J Cardiol 216:68–77

  10. 10.

    Xie X, Liu Y, Perkovic V, Li X, Ninomiya T, Hou W et al (2016) Renin-Angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials. Am J Kidney Dis 67(5):728–741

  11. 11.

    Cohen DL, Townsend RR (2008) What should the physician do when creatinine increases after starting an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker? J Clin Hypertens 10(10):803–804

  12. 12.

    Ahmed AK, Kamath NS, El Kossi M, El Nahas AM (2010) The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease. Nephrol Dial Transplant 25(12):3977–3982

  13. 13.

    Bhandari S, Ives N, Brettell EA, Valente M, Cockwell P, Topham PS et al (2016) Multicentre randomized controlled trial of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker withdrawal in advanced renal disease: the STOP-ACEi trial. Nephrol Dial Transplant 31(2):255–261

  14. 14.

    Levin A, Rigatto C, Barrett B, Madore F, Muirhead N, Holmes D et al (2014) Biomarkers of inflammation, fibrosis, cardiac stretch and injury predict death but not renal replacement therapy at 1 year in a Canadian chronic kidney disease cohort. Nephrol Dial Transplant 29(5):1037–1047

  15. 15.

    Speer T, Zewinger S, Fliser D (2013) Uraemic dyslipidaemia revisited: role of high-density lipoprotein. Nephrol Dial Transplant 28(10):2456–2463

  16. 16.

    Mafham M, Haynes R (2018) PCSK9 inhibition: ready for prime time in CKD? Kidney Int 93(6):1267–1269

  17. 17.

    Winkelmayer WC, Glynn RJ, Levin R, Owen WF Jr., Avorn J (2001) Determinants of delayed nephrologist referral in patients with chronic kidney disease. Am J Kidney Dis 38(6):1178–1184

  18. 18.

    Wang X, Shapiro JI (2019) Evolving concepts in the pathogenesis of uraemic cardiomyopathy. Nat Rev Nephrol 15(3):159–175

  19. 19.

    McAlister FA, Ezekowitz J, Tarantini L, Squire I, Komajda M, Bayes-Genis A et al (2012) Renal dysfunction in patients with heart failure with preserved versus reduced ejection fraction: impact of the new Chronic Kidney Disease-Epidemiology Collaboration Group formula. Circ Heart Fail 5(3):309–314

  20. 20.

    Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray DC, Barre PE (1996) Outcome and risk factors for left ventricular disorders in chronic uraemia. Nephrol Dial Transplant 11(7):1277–1285

  21. 21.

    Zoccali C, Mallamaci F, Tripepi G, Parlongo S, Cutrupi S, Benedetto FA et al (2002) Norepinephrine and concentric hypertrophy in patients with end-stage renal disease. Hypertension 40(1):41–46

  22. 22.

    Reddy YNV, Obokata M, Dean PG, Melenovsky V, Nath KA, Borlaug BA (2017) Long-term cardiovascular changes following creation of arteriovenous fistula in patients with end stage renal disease. Eur Heart J 38(24):1913–1923

  23. 23.

    Yamada S, Ishii H, Takahashi H, Aoyama T, Morita Y, Kasuga H et al (2010) Prognostic value of reduced left ventricular ejection fraction at start of hemodialysis therapy on cardiovascular and all-cause mortality in end-stage renal disease patients. Clin J Am Soc Nephrol 5(10):1793–1798

  24. 24.

    Kramann R, Erpenbeck J, Schneider RK, Rohl AB, Hein M, Brandenburg VM et al (2014) Speckle tracking echocardiography detects uremic cardiomyopathy early and predicts cardiovascular mortality in ESRD. J Am Soc Nephrol 25(10):2351–2365

  25. 25.

    House AA, Wanner C, Sarnak MJ, Pina IL, McIntyre CW, Komenda P et al (2019) Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 95(6):1304–1317

  26. 26.

    Weir MA, Dixon SN, Fleet JL, Roberts MA, Hackam DG, Oliver MJ et al (2015) beta-Blocker dialyzability and mortality in older patients receiving hemodialysis. J Am Soc Nephrol 26(4):987–996

  27. 27.

    Burnier M (2019) Should we eat more potassium to better control blood pressure in hypertension? Nephrol Dial Transplant 34(2):184–193

  28. 28.

    Ellison DH, Terker AS (2015) Why your mother was right: how potassium intake reduces blood pressure. Trans Am Clin Climatol Assoc 126:46–55

  29. 29.

    Bae EH, Lim SY, Cho KH, Choi JS, Kim CS, Park JW et al (2012) GFR and cardiovascular outcomes after acute myocardial infarction: results from the Korea Acute Myocardial Infarction Registry. Am J Kidney Dis 59(6):795–802

  30. 30.

    Szummer K, Lundman P, Jacobson SH, Schon S, Lindback J, Stenestrand U et al (2010) Relation between renal function, presentation, use of therapies and in-hospital complications in acute coronary syndrome: data from the SWEDEHEART register. J Intern Med 268(1):40–49

  31. 31.

    Herzog CA, Littrell K, Arko C, Frederick PD, Blaney M (2007) Clinical characteristics of dialysis patients with acute myocardial infarction in the United States: a collaborative project of the United States Renal Data System and the National Registry of Myocardial Infarction. Circulation 116(13):1465–1472

  32. 32.

    Sharma R, Pellerin D, Gaze DC, Gregson H, Streather CP, Collinson PO et al (2005) Dobutamine stress echocardiography and the resting but not exercise electrocardiograph predict severe coronary artery disease in renal transplant candidates. Nephrol Dial Transplant 20(10):2207–2214

  33. 33.

    Untersteller K, Girerd N, Duarte K, Rogacev KS, Seiler-Mussler S, Fliser D et al (2016) NT-proBNP and echocardiographic parameters for prediction of cardiovascular outcomes in patients with CKD stages G2-G4. Clin J Am Soc Nephrol 11(11):1978–1988

  34. 34.

    Wang LW, Fahim MA, Hayen A, Mitchell RL, Baines L, Lord S et al (2011) Cardiac testing for coronary artery disease in potential kidney transplant recipients. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD008691.pub2

  35. 35.

    Winther S, Svensson M, Jorgensen HS, Bouchelouche K, Gormsen LC, Pedersen BB et al (2015) Diagnostic performance of coronary CT angiography and myocardial perfusion imaging in kidney transplantation candidates. JACC Cardiovasc Imaging 8(5):553–562

  36. 36.

    Leyba K, Wagner B (2019) Gadolinium-based contrast agents: why nephrologists need to be concerned. Curr Opin Nephrol Hypertens 28(2):154–162

  37. 37.

    Schieda N, Blaichman JI, Costa AF, Glikstein R, Hurrell C, James M et al (2018) Gadolinium-based contrast agents in kidney disease: a comprehensive review and clinical practice guideline issued by the Canadian Association of Radiologists. Can J Kidney Health Dis 5:2054358118778573

  38. 38.

    Rodby RA (2008) Dialytic therapies to prevent NSF following gadolinium exposure in high-risk patients. Semin Dial 21(2):145–149

  39. 39.

    Breidthardt T, Burton JO, Odudu A, Eldehni MT, Jefferies HJ, McIntyre CW (2012) Troponin T for the detection of dialysis-induced myocardial stunning in hemodialysis patients. Clin J Am Soc Nephrol 7(8):1285–1292

  40. 40.

    Kraus D, von Jeinsen B, Tzikas S, Palapies L, Zeller T, Bickel C et al (2018) Cardiac troponins for the diagnosis of acute myocardial infarction in chronic kidney disease. J Am Heart Assoc 7(19):e8032

  41. 41.

    Wilhelm-Leen E, Montez-Rath ME, Chertow G (2017) Estimating the risk of radiocontrast-associated nephropathy. J Am Soc Nephrol 28(2):653–659

  42. 42.

    James MT, Ghali WA, Knudtson ML, Ravani P, Tonelli M, Faris P et al (2011) Associations between acute kidney injury and cardiovascular and renal outcomes after coronary angiography. Circulation 123(4):409–416

  43. 43.

    Shlipak MG, Heidenreich PA, Noguchi H, Chertow GM, Browner WS, McClellan MB (2002) Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. Ann Intern Med 137(7):555–562

  44. 44.

    Vogt B, Ferrari P, Schonholzer C, Marti HP, Mohaupt M, Wiederkehr M et al (2001) Prophylactic hemodialysis after radiocontrast media in patients with renal insufficiency is potentially harmful. Am J Med 111(9):692–698

  45. 45.

    Shaw C, Nitsch D, Lee J, Fogarty D, Sharpe CC (2016) Impact of an early invasive strategy versus conservative strategy for unstable angina and non-ST elevation acute coronary syndrome in patients with chronic kidney disease: a systematic review. PLoS ONE 11(5):e153478

  46. 46.

    Hemmelgarn BR, Southern D, Culleton BF, Mitchell LB, Knudtson ML, Ghali WA et al (2004) Survival after coronary revascularization among patients with kidney disease. Circulation 110(14):1890–1895

  47. 47.

    Turakhia MP, Blankestijn PJ, Carrero JJ, Clase CM, Deo R, Herzog CA et al (2018) Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Eur Heart J 39(24):2314–2325

  48. 48.

    Alonso A, Lopez FL, Matsushita K, Loehr LR, Agarwal SK, Chen LY et al (2011) Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 123(25):2946–2953

  49. 49.

    Bansal N, Fan D, Hsu CY, Ordonez JD, Marcus GM, Go AS (2013) Incident atrial fibrillation and risk of end-stage renal disease in adults with chronic kidney disease. Circulation 127(5):569–574

  50. 50.

    Winkelmayer WC, Patrick AR, Liu J, Brookhart MA, Setoguchi S (2011) The increasing prevalence of atrial fibrillation among hemodialysis patients. J Am Soc Nephrol 22(2):349–357

  51. 51.

    Buiten MS, de Bie MK, Rotmans JI, Gabreels BA, van Dorp W, Wolterbeek R et al (2014) The dialysis procedure as a trigger for atrial fibrillation: new insights in the development of atrial fibrillation in dialysis patients. Heart 100(9):685–690

  52. 52.

    Holden RM, Booth SL (2007) Vascular calcification in chronic kidney disease: the role of vitamin K. Nat Clin Pract Nephrol 3(10):522–523

  53. 53.

    Kidney Disease (2013) Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl 3:1–150

  54. 54.

    Arrigo M, Cippà PE, Mebazaa A (2018) Cardiorenal Interactions Revisited: How to Improve Heart Failure Outcomes in Patients With Chronic Kidney Disease. Curr Heart Fail Rep 15(5):307–314

  55. 55.

    Stamellou E, Floege J (2018) Novel oral anticoagulants in patients with chronic kidney disease and atrial fibrillation. Nephrol Dial Transplant 33(10):1683–1689

Download references

Author information

Correspondence to Dr. med. Turgay Saritas.

Ethics declarations

Conflict of interest

T. Saritas and J. Floege declare that they have no competing interests.

For this article no studies with human participants or animals were performed by any of the authors. All studies performed were in accordance with the ethical standards indicated in each case.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Saritas, T., Floege, J. Cardiovascular disease in patients with chronic kidney disease. Herz (2020). https://doi.org/10.1007/s00059-019-04884-0

Download citation

Keywords

  • Coronary artery disease
  • Renal insufficiency
  • Kidney failure
  • Risk factors
  • Epidemiology

Schlüsselwörter

  • Koronare Herzkrankheit
  • Renale Insuffizienz
  • Nierenversagen
  • Risikofaktoren
  • Epidemiologie